FECH：影响 CAR-T 细胞表型与功能的新型代谢靶点

FECH, a novel metabolic target influencing CAR T-cell phenotype and function.

靶向 PDPN 与 GD2 的新型 CAR-T 细胞组合以克服胶质母细胞瘤异质性

Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity.

这种新型 PDPN/GD2 CAR-T 细胞混合物在晚期临床前胶质母细胞瘤模型中显示出强效疗效，提示其具有治疗异质性胶质母细胞瘤和解决单抗原 CAR-T 细胞疗法相关局限性的潜力。

PDPN 与 GD2 双靶向增强 CAR-T 细胞对胶质母细胞瘤的疗效并促进持久肿瘤控制

Dual targeting of PDPN and GD2 enhances CAR T cell efficacy against glioblastoma and promotes durable tumor control.

CAR-T 细胞：改善儿童肿瘤结局所缺失的一环？

CAR T cells: the missing piece needed to improve outcomes for children with cancer?

人脑干类器官中 H3.3K27M 改变的弥漫性中线胶质瘤用于解析 GD2 CAR-T 细胞功能

De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell function.

靶向糖蛋白 GD2 的 CAR-T 细胞在高危室管膜瘤模型中显示强效抗肿瘤疗效

CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models.

胶质母细胞瘤的代谢与翻译后脆弱性：二硫死亡、糖基化及对 CAR-T 治疗的启示

Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.

儿童和年轻成人原发性中枢神经系统肿瘤的 CAR-T 细胞疗法：早期临床试验的系统综述，重点关注弥漫性中线胶质瘤

Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clini

初步临床经验表明，针对儿童和年轻成人 CNS 肿瘤的 CAR-T 细胞疗法具有生物学活性且临床可行，其毒性特征独特但可控。

靶向 GD2 的瞬时 mRNA CAR-T 细胞在弥漫性中线胶质瘤和高级别胶质瘤模型中提供剂量调整的疗效

Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models.

我们的结果表明，瘤内递送的瞬时 mRNA CAR-T 细胞具有实用价值，能够以明确的半衰期提供有效的肿瘤杀伤，并允许对剂量和潜在副作用进行调控。

工程化声遗传 EchoBack-CAR-T 细胞

Engineering sonogenetic EchoBack-CAR T cells.